Validity and Future of Primary Androgen Deprivation Therapy in Prostate Cancer. Integration in the Era of New Agents Targeting the Androgen Receptor
-
-
[1] Servicio de Urología, Hospital Universitario Puerta de Hierro-Majadahonda, 28222 Madrid, España
-
- Localización: Archivos españoles de urología, ISSN 0004-0614, Tomo 76, Nº. 1, 2023, págs. 1-28
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
The relationship of sex hormones with prostate glandular activity and the evidence of the favourable impact of bilateral orchiectomy in 21 patients with locally advanced or metastatic prostate cancer (PCa), ratified by Huggins C.B. and cols. in 1941, is one of the pillars for the acceptance of androgen deprivation therapy (ADT). Its clinical relevance has withstood the passage of time and remains valid, fundamentally, in advanced PCa. ADT has expanded its use over the years and, after extensive clinical experience, substantial modifications have been incorporated into its indications and options, both of which are increasingly precise. The objective of this review is to update the therapeutic positioning of primary ADT, genetic-molecular advances and future of the developing treatments of PCa.
